Download PDF
Zeitschrift für Orthomolekulare Medizin 2017; 15(02): 7-18
DOI: 10.1055/s-0043-113077
Wissen
Karl F. Haug Verlag in Georg Thieme Verlag KG Stuttgart – New York

Krebs: Mikronährstoffe in der onkologischen Intervention

Uwe Gröber
,
Peter Holzhauer
,
Irenäus Adamietz
Further Information

Publication History

Publication Date:
14 July 2017 (online)

    Permissions and Reprints

Summary

Aktuelle Studien weisen darauf hin, dass der labordiagnostisch validierte und therapieangepasste Einsatz von Mikronährstoffen ein wichtiger Baustein supportiver und komplementäronkologischer Therapiekonzepte ist. Die optimale Versorgung mit Nahrungsenergie sowie antientzündlichen und immunstabilisierenden Mikronährstoffen wie Selen, L-Carnitin, Vitamin C und D steigert das Ansprechen auf antineoplastische Therapien und verringert die Nebenwirkungsrate. Lebensqualität und Prognose der Patienten können verbessert werden.

Keywords

Krebs - Mikronährstoffe - Malnutrition - Supportivtherapie - Magnesium - Vitamin D - Bisphosphonate - Selen - L-Carnitin - Vitamin C
 

  • Literatur

  • 1 Bray F, Jemal A, Grey N. et al. Global cancer transitions according to the Human Development Index (2008–2030): A population-based study. Lancet Oncol 2012; 13: 790-801
    CrossrefPubMedGoogle Scholar
  • 2 American Cancer Society Global Cancer: Facts and Figures. 3. Aufl. New York: American Cancer Society; 2015
    Google Scholar
  • 3 Gröber U. Antioxidants and other micronutrients in complementary oncology. Breast Care 2009; 4 (01) 13-20
    CrossrefPubMedGoogle Scholar
  • 4 Ströhle A, Zänker K, Hahn A. Nutrition in oncology: the case of micronutrients. Oncol Rep 2010; 24 (04) 815-828
    PubMedGoogle Scholar
  • 5 Gröber U, Holzhauer P, Kisters K. et al. Micronutrients in Oncological Intervention. Nutrients 2016; 8 (03) 163
    CrossrefPubMedGoogle Scholar
  • 6 Gröber U, Hübner J, Holzhauer P, Kleeberg UR. Antioxidanzien und andere Mikronährstoffe in der komplementären Onkologie. Onkologe 2010; 16: 73-79
    CrossrefGoogle Scholar
  • 7 Micke O, Bruns F, Glatzel M. et al. Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology. European Journal of Integrative Medicine 2009; 1: 22-30
    Google Scholar
  • 8 D’Andrea G. Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin 2005; 55 (05) 319-321
    CrossrefPubMedGoogle Scholar
  • 9 Block KI. et al. Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials. Cancer Treat Rev 2007; 33 (05) 407-418
    CrossrefPubMedGoogle Scholar
  • 10 Block KI. et al. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 2008; 123 (06) 1227-1239
    CrossrefPubMedGoogle Scholar
  • 11 Mücke R, Schomburg L, Büntzel J. et al. Komplementärer Seleneinsatz in der Onkologie. Der Onkologe, 2010; 16: 181-186
    CrossrefGoogle Scholar
  • 12 Gröber U. Arzneimittel und Mikronährstoffe. 3. Aufl. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2014
    Google Scholar
  • 13 Tong H, Isenring E, Yates P. The prevalence of nutrition impact symptoms and their relationship to quality of life and clinical outcomes in medical oncology patients. Support Care Cancer 2009; 17 (01) 83-90
    CrossrefPubMedGoogle Scholar
  • 14 Bozzetti F. SCRINIO Working Group Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients. Support Care Cancer 2009; 17 (03) 279-284
    CrossrefPubMedGoogle Scholar
  • 15 Holzhauer P, Gröber U. Titel Der Gynäkologe 2016; Volume: Seitenzahl
  • 16 Fakih M. Anti-EGFR monoclonal antibody-induced hypomagnesaemia. Lancet Oncol 2007; 8 (05) 366-367
    CrossrefPubMedGoogle Scholar
  • 17 Vickers MM, Karapetis CS, Tu D. et al. Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Ann Oncol. 2013; 24 (04) 953-960
    CrossrefPubMedGoogle Scholar
  • 18 Knijn N, Tol J, Koopman M. et al. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer 2011; 47 (03) 369-374
    CrossrefPubMedGoogle Scholar
  • 19 Chen P, Wang L, Li H. et al. Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis. Oncol Lett 2013; 5 (06) 1915-1920
    CrossrefPubMedGoogle Scholar
  • 20 McDonnell SL, Baggerly C, French CB. et al. Serum 25-Hydroxyvitamin D Concentrations ≥40 ng/ml Are Associated with > 65 % Lower Cancer Risk: Pooled Analysis of Randomized Trial and Prospective Cohort Study. PLoS One 2016; 11 (04) e0152441
    CrossrefPubMedGoogle Scholar
  • 21 Gröber U, Kisters K. Influence of drugs on vitamin D and calcium metabolism. Dermatoendocrinol 2012; 4 (02) 158-166
    CrossrefPubMedGoogle Scholar
  • 22 Gröber U, Spitz J, Reichrath J. et al. Vitamin D: Update 2013: From rickets prophylaxis to general preventive healthcare. Dermatoendocrinol 2013; 5 (03) 331-347
    CrossrefPubMedGoogle Scholar
  • 23 Fink M. Vitamin D deficiency is a cofactor of chemotherapy-induced mucocutaneous toxicity and dysgeusia. J Clin Oncol 2011; 29 (04) e81-e82
    CrossrefPubMedGoogle Scholar
  • 24 Prieto-Alhambra D, Javaid MK, Servitja S. et al. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospectiv cohort study. Breast Cancer Res Treat 2011; 125 (03) 869-878
    CrossrefPubMedGoogle Scholar
  • 25 Khan QJ, Reddy PS, Kimler BF. et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 2010; 119 (01) 111-118
    CrossrefPubMedGoogle Scholar
  • 26 Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med 2010; 363 (21) 2027-2035
    CrossrefPubMedGoogle Scholar
  • 27 Carmel AS, Shieh A, Bang H, Bockman RS. The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥ 33 ng/ml. Osteoporos Int 2012; 23 (10) 2479-2487
    CrossrefPubMedGoogle Scholar
  • 28 Berruti A, Cook R, Saad F. et al. Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. Oncologist 2012; 17 (05) 645-652
    CrossrefPubMedGoogle Scholar
  • 29 Bedogni A, Saia G, Bettini G. et al. Osteomalacia: the missing link in the pathogenesis of bisphosphonate-related osteonecrosis of the jaws?. Oncologist 2012; 17 (08) 1114-1119
    CrossrefPubMedGoogle Scholar
  • 30 Bergman P, Sperneder S, Höijer J. et al. Low vitamin d levels are associated with higher opioid dose in palliative cancer patients – results from an observational study in sweden. PLoS One 2015; 10 (05) e0128223
    CrossrefPubMedGoogle Scholar
  • 31 Dev R, Del Fabbro E, Schwartz GG. et al. Preliminary report: vitamin D deficiency in advanced cancer patients with symptoms of fatigue or anorexia. Oncologist 2011; 16 (11) 1637-1641
    CrossrefPubMedGoogle Scholar
  • 32 Khan QJ, Reddy PS, Kimler BF. et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 2010; 119 (01) 111-118
    CrossrefPubMedGoogle Scholar
  • 33 Bittenbring JT, Neumann F, Altmann B. et al. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. J Clin Oncol 2014; 32 (29) 3242-3248
    CrossrefPubMedGoogle Scholar
  • 34 Gröber U, Holick MF. Vitamin D: Die Heilkraft des Sonnenvitamins. 3., vollst. überarb. und erweiterte Aufl. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2015
    Google Scholar
  • 35 Gröber U, Holzhauer P, Kisters K. Besser durch die Krebstherapie. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2014
    Google Scholar
  • 36 Bellinger F P, Raman AV, Reeves MA, Berry MJ. Regulation and function of selenoproteins in human disease. Biochem J 2009; 422: 11-22
    CrossrefPubMedGoogle Scholar
  • 37 Wallenberg M, Misra S, Wasik AM. et al. Selenium induces a multi-targeted cell death process in addition to ROS formation. J. Cell Mol Med 2014; 18: 671-684
    CrossrefPubMedGoogle Scholar
  • 38 Wallenberg M, Misra S, Björnstedt M. Selenium cytotoxicity in cancer. Basic Clin Pharmacol Toxicol 2014; 114: 377-386
    CrossrefPubMedGoogle Scholar
  • 39 Dennert G, Zwahlen M, Brinkman M. et al. Selenium for preventing cancer. Cochrane Database Syst Rev 2011; (05) CD005195 doi: 10.1002/14651858.CD005195
    PubMedGoogle Scholar
  • 40 Vinceti M, Dennert G, Crespi CM. et al. Selenium for preventing cancer. Cochrane Database Syst Rev. 2014; (03) CD005195 doi: 10.1002/14651858.CD005195.pub3
    PubMedGoogle Scholar
  • 41 Brodin O, Eksborg S, Wallenberg M. et al. Pharmacokinetics and toxicity of sodium selenite in the treatment of patients with carcinoma in a phase I clinical trial: The SECAR Study. Nutrients 2015; 7: 4978-4994
    CrossrefPubMedGoogle Scholar
  • 42 Son H, Lee SM, Yoon RG. et al. Effect of selenium supplementation for protection of salivary glands from iodine-131 radiation damage in patients with differentiated thyroid cancer. Hell J Nucl Med 2017; 20 (01) 62-70
    PubMedGoogle Scholar
  • 43 Khasabova IA. Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. J Neurosci 2012; 32 (20) 7091-7101
    CrossrefPubMedGoogle Scholar
  • 44 Visovsky C. et al. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin JOncol Nurs 2007; 11 (06) 901-913
    Google Scholar
  • 45 Sun Y. et al. A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine ALC) in treatment of chemotherapy-induced peripheral neuropathy (CPIN). J Clin Oncol 2012; 30: abstr 9017 (symptom management/supportivecare/palliativecare)
  • 46 Drisko JA, Chapman J, Hunter VJ. The use of antioxidants with firstline chemotherapy in two cases of ovarian cancer. J Am Coll Nutr 2003; 22: 118-123
    CrossrefPubMedGoogle Scholar
  • 47 Drisko J A, Chapman J, Hunter VJ. The use of antioxidant therapies during chemotherapy. Gynecol Oncol 2003; 88: 434-439
    CrossrefPubMedGoogle Scholar
  • 48 Vollbracht C, Schneider B, Leendert V. et al. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: Results of a retrospective, multicentre, epidemiological cohort study in Germany. Vivo 2011; 25: 983-990
    Google Scholar
  • 49 Welsh J L, Wagner B A, van’t Erve. et al. Pharmacological ascorbate with gemcitabine for the control of metastastic and node-positive pancreatic cancer (PACMAN): Results from a phase I clinical trial. Cancer Chemother Pharmacol 2013; 71: 765-775
    CrossrefPubMedGoogle Scholar
  • 50 Monti DA, Mitchell E, Bazzan AJ. et al. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS ONE 2012; 7: e29794
    CrossrefPubMedGoogle Scholar
  • 51 Seo MS, Kim JK, Shim JY. High-dose vitamin C promotes regression of multiple pulmonary metastases originating from hepatocellular carcinoma. Yonsei Med J 2015; 56: 1449-1452
    CrossrefPubMedGoogle Scholar
  • 52 PDQ Cancer Complementary and Alternative Medicine Editorial Board High-Dose Vitamin C (PDQ): Health Professional Version. PDQ Cancer Information Summaries; National Cancer Institute; Bethesda, MD, USA: 2002–2015
    Google Scholar